FY 2025 Results February 26, 2026 FY 2025 Results - 1 - Legal Disclaimer Important Information This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended and restated from time to ...

Financial Performance - H1 2025 revenue reached €3677 million, a 70% increase at constant currency (cc)[14] - H1 2025 adjusted EBITDA was €876 million, up 127% cc[14] - Free cash flow pre-M&A for H1 2025 was -€14 million, an improvement of €182 million compared to H1 2024[-196 million][14] - The leverage ratio decreased to 42x in H1 2025, compared to 46x at the end of FY24[14] Business Segment Performance - Biopharma revenue grew by 82% cc in H1 2025[17] - Diagnostic revenue increased by 28% cc in H1 2025[23] Margin Expansion - Adjusted EBITDA margin increased by 80 bps in H1 2025, despite the IRA impact[17] - Like-for-like adjusted EBITDA margin increased by 171 bps in H1 2025[17] Capital Allocation - An interim dividend of €015 per share was reinstated[14] - Liquidity stands at €14 billion[43] Future Outlook - The company reaffirmed its 2025 guidance and improved its free cash flow pre-M&A guidance to €375 - €425 million[47]